News | April 21, 2015

First Irish Patient Treated for Prostate Cancer in Prague

Proton Therapy Center Czech uses seed markers for precise tumor targeting across five treatments

Proton Therapy Center Czech, John, Irish, U.K., prostate cancer

April 21, 2015 — The Proton Therapy Center in the Czech Republic treated its first Irish patient for prostate cancer beginning in mid-March.

The PTC is well known to the U.K. audience thanks to the story of the British boy Ashya King. Ashya’s parents chose Prague for his brain tumor treatment to ensure the lowest possible side effects. 

But from the U.K. it is mostly men in their fifties and sixties who come for the proton beam therapy in Prague. That's because proton therapy is highly beneficial for the major male problem of prostate cancer. 

John is 64. His family and background is in Ireland and he often still returns to his home country. He came to the U.K. to work, for more than 25 years, for the military forces.

"I was on active surveillance for 18 months back home but felt like I was awaiting something to happen“, said John, describing his feelings of uncertainty. "At that time, I came across the stories of British patients treated in Prague and sat down to read PTC websites and watch the great videos of the center, located in a city I always wanted to visit. Of course there was also the story of Ashya King in the British media. “ 

John did not hesitate and decided for himself. "I just rang the head nurse of my urologist and announced that I was going for proton therapy. I got a message that the urologist was fine with that." Getting all the medical reports took a bit longer than he had imagined – it was Christmas time. "Once I had my folder I sent it to PTC. There the patient manager called Lucie immediately got in touch. She was very supportive and in constant touch. “

John had never visited Prague although he had always wanted to. He and his wife were impressed. "I liked [the] center from day one”, he said. That was when he came for his first consultation and planning of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Then he went back to the U.K. to get some things sorted and came back in mid-March to start his five sessions of treatment.

It consisted of five fractions only – a major advantage of proton beam therapy which enables higher doses onto the tumor, increasing the efficiency and minimizing the unwanted dose around the tumor. “In early stage cases of prostate cancer, PTC Czech has 97 percent curability and the data corresponds to the world clinical studies on proton therapy,” added Jiri Kubes, M.D., PTC medical director. This is also strengthened by the use of golden seeds – golden markers which help to target the beam even more precisely. These golden pellets are applied directly at PTC.

“So far I feel great,” said John.

For more information: www.proton-cancer-treament.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init